Grove Laboratories, Inc. v. Approved Pharmaceutical Corp.

149 F. Supp. 86, 112 U.S.P.Q. (BNA) 287, 1957 U.S. Dist. LEXIS 3827
CourtDistrict Court, N.D. New York
DecidedJanuary 2, 1957
DocketCiv. 4951
StatusPublished
Cited by6 cases

This text of 149 F. Supp. 86 (Grove Laboratories, Inc. v. Approved Pharmaceutical Corp.) is published on Counsel Stack Legal Research, covering District Court, N.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Grove Laboratories, Inc. v. Approved Pharmaceutical Corp., 149 F. Supp. 86, 112 U.S.P.Q. (BNA) 287, 1957 U.S. Dist. LEXIS 3827 (N.D.N.Y. 1957).

Opinion

BRENNAN, Chief Judge.

The complaint in this action, as supplemented, alleges two separate claims for relief. (1) A claim based upon the alleged infringement of plaintiff’s registered trademark. (2) A claim for relief based upon unfair competition in the use by the defendant of an alleged infringing mark. Jurisdiction of the court appears to be based both on diversity of citizenship and under the provisions of the Lanham Act, 15 U.S.C.A. §§ 1051-1127.

The answer of the defendant denies the material allegations of the complaint; alleges as a defense its own good faith and further alleges as a defense and counter-claim that the mark of the plaintiff is void and prays for its cancellation.

The issues created by the pleadings-principally involve (1) the validity of plaintiff’s mark; (2) the infringement and (3) the existence of a secondary meaning created by plaintiff’s mark. The likelihood of confusion of the source of the product to which plaintiff’s mark and the alleged infringing mark are attached, is an issue which may well be applicable to both the infringement and the unfair competition action. The action was tried to the court. The trial record is fairly lengthy. Very little, if any, of the evidence offered is disputed and the essential facts are summarized below.

Plaintiff is a Delaware corporation, having its principal place of business at St. Louis, Mo. For some years it has been engaged in the manufacture and sale to dealers of pharmaceutical products, including cold tablets, which since about 1935 have been distributed to retail outlets in a white cardboard, slide box, bearing the numeral “4” and the word “way” on a red background in a conspicuous position thereon. As so placed, the numeral “4” appears above the word “Way”. On the sides of the box are listed four effects or results to. be obtained by the use of the tablets.

The plaintiff’s mark “4 Way” was registered in the U. S. Patent Office on Feb. 26, 1935. This registration was under the 1905 Act. The mark was republished on Sept. 4, 1951 under the Act of 1946. The supplemental complaint alleges and the record shows that the mark was also registered in the U. S. Patent Office in 1954 or 1955 and in the State of New York on June 30, 1954 under appropriate state statutes.

Plaintiff’s product, contained in the box upon which the mark was affixed, consisted of a pink colored tablet intended to function so as to afford relief from common colds. It has been extensively and nationally advertised from 1935 to the present date at a total expenditure of over ten million dollars. The sales of the product have increased from year to year since 1935 and the total in money value exceeds twenty-seven mil *89 lion dollars. The annual sales appear to bear a somewhat consistent relationship to the amount of advertising expense. The tablets are extensively handled by retail distributors throughout the United States. The product is nationally known. The twelve tablet box is sold at retail for twenty-three cents.

The defendant is a New York corporation, doing business at Syracuse N. Y. Its business, which was started in June 1950, is likewise principally involved in pharmaceutical preparations or products. As to the item in controversy here, it purchases capsules, intended to afford relief in the case of colds, from a manufacturer and packages and distributes same principally to drug stores in Northeast United States, including Ohio, Pennsylvania, New York, Massachusetts and Connecticut. It packages its cold capsules in a glass bottle to which is attached a label which ■displays conspicuously the numeral “7” and the word “Way” in the following form — “7-Way”. Underneath or below the above numeral and word in a smaller type are the words “Cold Capsules” and underneath those two words “with •quinine”. The label lists seven ingredients apparently contained in each cap•sule.

Two-thirds of defendant’s cold capsules are labelled as above, the designation “7-Way” appearing on a salmon colored background. The remaining one-third is distributed in the same type of ■container and the label differs principally in that the name of the particular drug-store to which the defendant makes its sale is imprinted thereon — as for example — “Hammonds 7-Way Cold ■Capsules”. On each of such labels the words “7-Way” appear on a different col■ored background. It is evident that the ■volume of the cold capsules distributed by the defendant is not large when com■pared with that of the plaintiff. The ■amount of defendant’s sales does not ■appear in the record. Defendant does no advertising of its capsules except to provide a display carton or holder for ■■the use of the druggist or retail seller. The sixteen tablet bottle retails for forty-nine cents.

Evidence offered bearing upon the question of confusion or mistake as to the source or origin of the capsules was voluminous. In addition to some four or five witnesses who. testified at the trial, the plaintiff took the depositions of several witnesses at Albany N. Y., Erie Pa., Buffalo N. Y., and Cleveland O. To discuss their evidence in detail is unnecessary. It is sufficient to say that persons who might be termed prospective purchasers of cold remedies were called after having been shown the defendant’s packaged product with the “7-Way” legend thereon and were asked as to their reaction thereto. The replies were varied but there was substantial evidence to show that the 4-Way tablet was well known in the consumer trade and that the same was called for and purchased by customers using that designation or the designation of “4-Way Cold Tablets”. In other words, it was recognized by consumers as a brand name product. Substantial evidence also showed that upon being shown the container containing defendant’s product that the reaction was that it was an improved 4-Way cold remedy placed upon the market by the same company. The mark 7-Way in most instances invoked a mental association with the 4-Way product.

The defendant called three drug-store operators engaged in business at the city of Syracuse. They were permitted to express their opinions as to whether or not customer confusion would exist in the matter of the plaintiff’s and defendant’s product. Their replies were negative in effect and they further testified that no instances of actual customer consumer confusion came to their attention. With the above outline of facts, the applicable law will be briefly discussed.

Although no question was raised upon the trial, the defendant urges in the brief submitted that plaintiff has failed to show a use by the defendant of the alleged infringing name in interstate commerce. Even though *90 the point was not raised at the trial, there is sufficient evidence to satisfy the requirement of the statute. The managing agent of the defendant testified that the area of defendant's operations constituted northeast United States including five specific states, previously mentioned herein. In addition, the defendant offered in evidence as an exhibit a labelled bottled container of defendant’s product prepared for and apparently sold to a drug concern at Cleveland, Ohio. Plaintiff’s interstate use of its mark is plainly affected. The contention is rejected. Admiral Corp. v. Penco, Inc., 2 Cir., 203 F.2d 517, at page 520.

The validity of plaintiff’s mark would seem to be the next question to be decided.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Car-Freshner Corporation v. Turtle Wax, Inc.
268 F. Supp. 162 (S.D. New York, 1967)
Miles Laboratories, Inc. v. Frolich
195 F. Supp. 256 (S.D. California, 1961)
Travel Magazine, Inc. v. Travel Digest, Inc.
191 F. Supp. 830 (S.D. New York, 1961)

Cite This Page — Counsel Stack

Bluebook (online)
149 F. Supp. 86, 112 U.S.P.Q. (BNA) 287, 1957 U.S. Dist. LEXIS 3827, Counsel Stack Legal Research, https://law.counselstack.com/opinion/grove-laboratories-inc-v-approved-pharmaceutical-corp-nynd-1957.